Keywords: GlaxoSmithKline, Votrient, Soft tissue sarcomas, EMA, Approval

EMA approves GlaxoSmithKline's Votrient for soft tissue sarcomas

Article | 09 August 2012

Print This

UK pharma giant GlaxoSmithKline (LSE: GSK) says that the European Medicines Agency has approved Votrient (pazopanib) for the treatment of ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in